Dole Food Company Releases 2020 Corporate Responsibility & Sustainability Report
22.4.2020 16:00:00 EEST | Business Wire | Press release
Dole Food Company announced today the release of its 2020 Corporate Responsibility & Sustainability Report. The report unveils the organization’s new sustainability framework, “The Dole Way,” along with the company’s first-ever enterprise-wide sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005205/en/
Dole Fresh Fruit, Pineapple Farm (Photo: Business Wire)
“Since our founding, Dole has strived to deliver the best of which we are capable—in both our products and how we produce them,” stated Johan Linden, CEO of Dole. “The need for healthy food choices has never been more evident than during these past weeks as we adapt under this global pandemic. The journey and dedication to be a responsible citizen of our communities as well as a good steward of our land will continue into our future and Dole will remain steadfast in being honest and transparent about our efforts and our impacts in supplying wholesome food across the globe.”
“Of course,” Linden continued, “our stakeholders expect this of us, but even more we expect this of ourselves; to engage in open dialogue, including critical voices, to make a measurable and meaningful difference for people and the planet, and to constantly evaluate and improve. It’s what we believe is the right way to do business.”
Dole’s sustainability report outlines an ambitious slate of initiatives under the Dole Way framework focused on tangible action directed towards five key goals:
- More than ever, Dole understands our responsibility to positively impact underserved communities and promises to donate no less that 2,500 tons of fresh fruit and produce by 2025.
- Dole will effect valuable long-term change by declaring a social premium for Dole branded bananas and pineapple. This social investment will be directed by company organizations and independent foundations that have operated in Dole’s Latin American production areas for decades and will be invested in the communities according to local needs.
- Dole produce is grown in areas where water is becoming increasingly scarce, and Dole is committed to reduce water usage while improving water quality in its operations.
- Dole will continue to take action to promote healthy eating and nutrition education, with a special focus on youth. At its core, this is a promise to support people living longer and healthier lives.
- Dole recognizes that climate change is real and that the food and agriculture industries have a role to play in mitigating its effects. Dole will focus on decreasing its carbon footprint by ensuring new vessels include efficiency upgrades and working towards achieving net zero carbon emissions at farm level by 2030.
Other important sustainability targets include ensuring all packaging materials used in Dole’s banana and pineapple businesses are either recyclable or compostable by 2025, and introducing blockchain or similar technology in all operations to bring about a step-change in food safety and transparency.
Reporting on the impacts of Dole’s responsibility and sustainability goals is also of critical importance.
“This report and our goals are a new milestone in our sustainability pursuit, and farming is at the heart of that transformation. As farmers, we are facing the reality of climate change and are joining all other concerned people and businesses willing to tackle this challenge in our supply chain,” said Xavier Roussel, Vice President of Sustainability. “We will build on our learning—both in precision farming and organic agriculture—to deliver on our commitments in alliance with our business partners and other stakeholders. As an employer we will continue to make a difference in the lives of our employees and local communities and make a positive impact both within our farm borders and beyond.”
Added Roussel, “Dole is absolutely committed to being part of the community of concerned citizens taking on the sustainability challenge.”
To view all Dole’s achievements and goals click the link to the 2020 Corporate Responsibility & Sustainability Report click here.
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005205/en/
Contact information
US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
